Body Composition

HGH Fragment 176-191

Human Growth Hormone Fragment (176-191)

Pure lipolytic activity without the anabolic downsides

Research Status: Phase I/II completed AOD-9604 precursor GH Frag
Mechanism of Action

How it works

Fragment 176-191 is the C-terminal end of growth hormone responsible for its fat-burning effects. Unlike intact GH, it does not bind IGF-1 receptors and therefore does not stimulate growth or cause insulin resistance.

Areas of Research

What the research explores

In published research, HGH Fragment 176-191 has been studied in connection with the following. These describe findings reported in the literature — not approved uses, claims, or outcomes to expect.

  • Targeted stimulation of lipolysis (fat breakdown)
  • Does not cause hyperglycemia or insulin resistance
  • Does not affect IGF-1 levels
  • Preserves lean muscle during caloric restriction
  • Particularly effective on abdominal fat depots
  • No inhibition of endogenous GH production
Research Highlight

Controlled clinical studies confirmed HGH Fragment 176-191 stimulates lipolysis 12.5x more powerfully than GH while maintaining none of the diabetogenic effects.

Safety Profile

Adverse events & gaps

Favorable profile. No known metabolic side effects. Injection site reactions possible.



Stay Informed on
Peptide Research

Research summaries, newly documented peptides, and clinical trial updates delivered to your inbox.

No spam. Unsubscribe at any time.